title: The hypothalamic endocannabinoid system participates in the secretion of oxytocin and tumor necrosis factor-alpha induced by lipopolysaccharide.
abstract: This study investigated the participation of the hypothalamic endocannabinoid system in the response to lipopolysaccharide (LPS) challenge evaluating oxytocin (OXT) and tumor necrosis factor-alpha (TNF-alpha) plasma levels in vivo and their release from hypothalamic fragments in vitro. LPS increased OXT and TNF-alpha release through anandamide-activation of hypothalamic cannabinoid receptor CB(1,) since the antagonist AM251 blocked this effect. Anandamide, through its receptors, also increased hypothalamic nitric oxide (NO) which inhibited OXT release, ending the stimulatory effect of the endocannabinoid. Our findings reveal a hypothalamic interaction between oxytocin, endocannabinoid and NO-ergic systems providing a regulation of the hypothalamic-neurohypophyseal axis under basal and stress conditions.
authors.affiliation: Centro de Estudios Farmacológicos y Botánicos, CEFYBO-CONICET-UBA, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. andredelaurentiis@yahoo.com
authors.forename: Andrea
authors.initials: A
authors.lastname: De Laurentiis
authors.forename: Javier
authors.initials: J
authors.lastname: Fernandez-Solari
authors.forename: Claudia
authors.initials: C
authors.lastname: Mohn
authors.forename: Berenice
authors.initials: B
authors.lastname: Burdet
authors.forename: María A
authors.initials: MA
authors.lastname: Zorrilla Zubilete
authors.forename: Valeria
authors.initials: V
authors.lastname: Rettori
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D001549:Benzamides / Q000494:pharmacology; D063385:Cannabinoid Receptor Modulators / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000494:pharmacology; D002219:Carbamates / Q000494:pharmacology; D063388:Endocannabinoids; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005786:Gene Expression Regulation / Q000187:drug effects; D007031:Hypothalamus / Q000187:drug effects* / Q000378:metabolism; D007211:Indoles / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D009569:Nitric Oxide / Q000378:metabolism; D010121:Oxytocin / Q000097:blood*; D053284:Polyunsaturated Alkamides / Q000494:pharmacology; D011863:Radioimmunoassay / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D043884:Receptor, Cannabinoid, CB1 / Q000235:genetics / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*
chemical_list: D001095:Arachidonic Acids; D001549:Benzamides; D063385:Cannabinoid Receptor Modulators; D002219:Carbamates; D063388:Endocannabinoids; D007211:Indoles; D008070:Lipopolysaccharides; D053284:Polyunsaturated Alkamides; D043884:Receptor, Cannabinoid, CB1; D014409:Tumor Necrosis Factor-alpha; C500528:cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester; D009569:Nitric Oxide; D010121:Oxytocin; C094023:iodopravadoline; C078814:anandamide